These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29259100)

  • 21. Longitudinal Characterization of mGluR5 Using
    Bertoglio D; Kosten L; Verhaeghe J; Thomae D; Wyffels L; Stroobants S; Wityak J; Dominguez C; Mrzljak L; Staelens S
    J Nucl Med; 2018 Nov; 59(11):1722-1727. PubMed ID: 29794227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IKKβ slows Huntington's disease progression in R6/1 mice.
    Ochaba J; Fote G; Kachemov M; Thein S; Yeung SY; Lau AL; Hernandez S; Lim RG; Casale M; Neel MJ; Monuki ES; Reidling J; Housman DE; Thompson LM; Steffan JS
    Proc Natl Acad Sci U S A; 2019 May; 116(22):10952-10961. PubMed ID: 31088970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correction of Huntington's Disease Phenotype by Genistein-Induced Autophagy in the Cellular Model.
    Pierzynowska K; Gaffke L; Hać A; Mantej J; Niedziałek N; Brokowska J; Węgrzyn G
    Neuromolecular Med; 2018 Mar; 20(1):112-123. PubMed ID: 29435951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulating FKBP5/FKBP51 and autophagy lowers HTT (huntingtin) levels.
    Bailus BJ; Scheeler SM; Simons J; Sanchez MA; Tshilenge KT; Creus-Muncunill J; Naphade S; Lopez-Ramirez A; Zhang N; Lakshika Madushani K; Moroz S; Loureiro A; Schreiber KH; Hausch F; Kennedy BK; Ehrlich ME; Ellerby LM
    Autophagy; 2021 Dec; 17(12):4119-4140. PubMed ID: 34024231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
    Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
    Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
    Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
    Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.
    Alpaugh M; Masnata M; de Rus Jacquet A; Lepinay E; Denis HL; Saint-Pierre M; Davies P; Planel E; Cicchetti F
    Mol Ther; 2022 Apr; 30(4):1500-1522. PubMed ID: 35051614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
    Shekhar S; Vatsa N; Kumar V; Singh BK; Jamal I; Sharma A; Jana NR
    Hum Mol Genet; 2017 Jan; 26(2):420-429. PubMed ID: 28007908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease.
    Kacher R; Lamazière A; Heck N; Kappes V; Mounier C; Despres G; Dembitskaya Y; Perrin E; Christaller W; Sasidharan Nair S; Messent V; Cartier N; Vanhoutte P; Venance L; Saudou F; Néri C; Caboche J; Betuing S
    Brain; 2019 Aug; 142(8):2432-2450. PubMed ID: 31286142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation and Characterization of Knock-in Mouse Models Expressing Versions of Huntingtin with Either an N17 or a Combined PolyQ and Proline-Rich Region Deletion.
    André EA; Braatz EM; Liu JP; Zeitlin SO
    J Huntingtons Dis; 2017; 6(1):47-62. PubMed ID: 28211815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.
    Heikkinen T; Lehtimäki K; Vartiainen N; Puoliväli J; Hendricks SJ; Glaser JR; Bradaia A; Wadel K; Touller C; Kontkanen O; Yrjänheikki JM; Buisson B; Howland D; Beaumont V; Munoz-Sanjuan I; Park LC
    PLoS One; 2012; 7(12):e50717. PubMed ID: 23284644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation.
    Pierzynowska K; Podlacha M; Gaffke L; Rintz E; Wiśniewska K; Cyske Z; Węgrzyn G
    Autophagy; 2024 May; 20(5):1159-1182. PubMed ID: 37992314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.
    Schiefer J; Sprünken A; Puls C; Lüesse HG; Milkereit A; Milkereit E; Johann V; Kosinski CM
    Brain Res; 2004 Sep; 1019(1-2):246-54. PubMed ID: 15306259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations of striatal indirect pathway neurons precede motor deficits in two mouse models of Huntington's disease.
    Sebastianutto I; Cenci MA; Fieblinger T
    Neurobiol Dis; 2017 Sep; 105():117-131. PubMed ID: 28578004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Silva FR; Olmo IG; Carvalho TG; Alves-Silva J; Ferreira-Vieira TH; Santos JT; Xavier CQS; Silva NC; Maciel EMA; Conn PJ; Ribeiro FM
    J Neurochem; 2018 Oct; 147(2):222-239. PubMed ID: 30028018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes.
    Southwell AL; Smith-Dijak A; Kay C; Sepers M; Villanueva EB; Parsons MP; Xie Y; Anderson L; Felczak B; Waltl S; Ko S; Cheung D; Dal Cengio L; Slama R; Petoukhov E; Raymond LA; Hayden MR
    Hum Mol Genet; 2016 Sep; 25(17):3654-3675. PubMed ID: 27378694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AUTEN-67 (Autophagy Enhancer-67) Hampers the Progression of Neurodegenerative Symptoms in a Drosophila model of Huntington's Disease.
    Billes V; Kovács T; Hotzi B; Manzéger A; Tagscherer K; Komlós M; Tarnóci A; Pádár Z; Erdős A; Bjelik A; Legradi A; Gulya K; Gulyás B; Vellai T
    J Huntingtons Dis; 2016 May; 5(2):133-47. PubMed ID: 27163946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute manganese treatment restores defective autophagic cargo loading in Huntington's disease cell lines.
    Bryan MR; O'Brien MT; Nordham KD; Rose DIR; Foshage AM; Joshi P; Nitin R; Uhouse MA; Di Pardo A; Zhang Z; Maglione V; Aschner M; Bowman AB
    Hum Mol Genet; 2019 Nov; 28(22):3825-3841. PubMed ID: 31600787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux.
    Lee H; Noh JY; Oh Y; Kim Y; Chang JW; Chung CW; Lee ST; Kim M; Ryu H; Jung YK
    Hum Mol Genet; 2012 Jan; 21(1):101-14. PubMed ID: 21954231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
    Ma Q; Yang J; Li T; Milner TA; Hempstead BL
    Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.